-
-
公开(公告)号:US20240335382A1
公开(公告)日:2024-10-10
申请号:US18747485
申请日:2024-06-19
发明人: Giorgio Dell'Acqua , Pamela Scoca , Roland Peralta
IPC分类号: A61K9/107 , A61K8/06 , A61K8/92 , A61K36/53 , A61K36/534 , A61K36/71 , A61K45/06 , A61K47/14 , A61K47/24 , A61K47/44 , A61K47/46 , A61P17/14 , A61Q7/00
CPC分类号: A61K9/1075 , A61K8/068 , A61K8/922 , A61K36/53 , A61K36/534 , A61K36/71 , A61K45/06 , A61K47/14 , A61K47/24 , A61K47/44 , A61K47/46 , A61P17/14 , A61Q7/00
摘要: The present disclosure provides all-natural nano- or micro-emulsions for the treatment of the skin, hair follicles, and related conditions, methods of using such nano- or micro-emulsions, and methods for preparing such nano- or micro-emulsions. The present disclosure relates to nano- or micro-emulsion formulations with improved bioavailability, time of onset, cellular permeability, and viscosity that can be suitable for topical, sublingual, oral, and/or nasal administrations. The current disclosure also includes compositions and methods for improving the bioavailability and the onset of actions arising from the particular components within the nano- or micro-emulsion formulations of the present disclosure.
-
公开(公告)号:US20240299481A1
公开(公告)日:2024-09-12
申请号:US18662946
申请日:2024-05-13
申请人: JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES , SAWAI PHARMACEUTICAL Co., Ltd.
发明人: Koichi WATASHI , Wakana SASO , Toru TERASHIMA
IPC分类号: A61K36/71 , A61K31/4375 , A61P31/14
CPC分类号: A61K36/71 , A61K31/4375 , A61P31/14
摘要: In an embodiment, a Stephania cepharantha-derived alkaloid-containing preparation for treatment of a novel coronavirus infection is provided. According to an embodiment of the present invention, a preparation for treatment of a novel coronavirus infection comprises Cepharanthine, Isotetrandrine, Cycleanine, and Berbamine. A preparation for treatment of a novel coronavirus infection is for treatment of an infection caused by the novel coronavirus mutant strain. According to an embodiment of the present invention, a Stephania cepharantha-derived alkaloid-containing preparation for treatment of a novel coronavirus infection is provided.
-
公开(公告)号:US20240293446A1
公开(公告)日:2024-09-05
申请号:US18661506
申请日:2024-05-10
申请人: Maishen Inc.
发明人: Dalong Zhang , Xinghe Chen , Eva Chen
IPC分类号: A61K33/06 , A23F3/34 , A61K35/02 , A61K36/484 , A61K36/71 , A61K36/736 , A61K36/78 , A61K36/8966 , A61K36/899 , A61K36/9068
CPC分类号: A61K33/06 , A23F3/34 , A61K35/02 , A61K36/484 , A61K36/71 , A61K36/736 , A61K36/78 , A61K36/8966 , A61K36/899 , A61K36/9068 , A61K2236/15 , A61K2236/17 , A61K2236/37
摘要: A method and composition to extract of several processed herbal medicinal plants and an herbal tea composition for ingestion which contains the extract. The functional herbal extraction method and composition is used to relieve the symptoms of cough and throat discomfort. This composition creates a synergy between different ingredients that works to suppress cough, yellow or green phlegm, sore throat and specifically to treat hot cough. The composition can include Shi Gao, Hai Fu Shi, Chuan Bei Mu, Tian Zhu Huang, Ban Xia, Yu Xing Cao, Tian Kui Zi, Gan Cao, Tian Nan Xing, Chai Hu, Huang Qin, Zhi Shi, Bai Shao, Chen Pi, Kuan Dong Hua, Zi Wan, Sheng Jiang. The effectiveness of the herbal tea is at least partially dependent on the desired means of preparation and administering the composition.
-
公开(公告)号:US20240285721A1
公开(公告)日:2024-08-29
申请号:US18659701
申请日:2024-05-09
发明人: Tomy YESUDAS , Philip ALEX , Michael CENTOLA , Adam Joshua PAYNE
IPC分类号: A61K36/90 , A61K36/185 , A61K36/22 , A61K36/23 , A61K36/24 , A61K36/27 , A61K36/28 , A61K36/29 , A61K36/31 , A61K36/35 , A61K36/48 , A61K36/66 , A61K36/68 , A61K36/71 , A61K36/76 , A61K36/77 , A61K36/808 , A61K36/899
CPC分类号: A61K36/90 , A61K36/185 , A61K36/22 , A61K36/23 , A61K36/24 , A61K36/27 , A61K36/28 , A61K36/29 , A61K36/31 , A61K36/35 , A61K36/48 , A61K36/66 , A61K36/68 , A61K36/71 , A61K36/76 , A61K36/77 , A61K36/808 , A61K36/899
摘要: Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.
-
76.
公开(公告)号:US20240238358A1
公开(公告)日:2024-07-18
申请号:US18561963
申请日:2021-12-29
发明人: Boli Zhang , Junhua Zhang , Qingquan Liu , Fengwen Yang , Ming Huang , Yongming Guo , Xinbo Song , Han Zhang , Yuefei Wang , Yanxu Chang , Erwei Liu , Wenke Zheng
IPC分类号: A61K36/258 , A61K9/16 , A61K36/076 , A61K36/233 , A61K36/284 , A61K36/484 , A61K36/539 , A61K36/57 , A61K36/71 , A61K36/752 , A61K36/808 , A61K36/85 , A61K36/8888 , A61K36/8968 , A61K36/899 , A61K36/8994
CPC分类号: A61K36/258 , A61K9/1623 , A61K36/076 , A61K36/233 , A61K36/284 , A61K36/484 , A61K36/539 , A61K36/57 , A61K36/71 , A61K36/752 , A61K36/808 , A61K36/85 , A61K36/8888 , A61K36/8968 , A61K36/899 , A61K36/8994 , A61K2236/331
摘要: A traditional Chinese medicine composition for infectious disease recovery, containing the Chinese medicinal herbs: 2-4 parts of ginseng, 4-8 parts of Ophiopogon japonicus, 2-4 parts of Schisandra chinensis berry, 6-10 parts of Wolfiporia extensa Ginns, 6-10 parts of rhizoma pinelliae, 4-8 parts of Scrophularia ningpoensis, 4-6 parts of stir-fried Atractylodes, 4-8 parts of mandarin orange peel, 2-4 parts of Glycyrrhiza uralensis, 4-8 parts of Bupleurum scorzonerifolium, 2-4 parts of Actaea cimicifuga, 8-12 parts of Coix lacryma-jobi, 8-12 parts of Scutellaria baicalensis, 8-12 parts of Verbena officinalis, 12-18 parts of rhizoma phragmitis, and 1-3 parts of Lophatherum gracile. The present traditional Chinese medicine composition can be used in medicines for the prevention, treatment, or alleviation of the sequelae or complications of infectious diseases or for the promotion of the functional recovery of damaged tissues, organs or systems caused by infectious diseases.
-
公开(公告)号:US20240226218A1
公开(公告)日:2024-07-11
申请号:US17912804
申请日:2021-03-19
发明人: Rachel ALKALAY
IPC分类号: A61K36/53 , A61K36/185 , A61K36/22 , A61K36/324 , A61K36/71 , A61P31/14
CPC分类号: A61K36/53 , A61K36/185 , A61K36/22 , A61K36/324 , A61K36/71 , A61P31/14
摘要: A method of preventing or treating Coronavirus infection in a subject in need thereof is provided. The method comprising administering to the subject an effective amount of a plant species or genus thereof-derived component selected from the group consisting of a plant part, extract thereof, fraction thereof, active ingredient thereof, synthetic analog thereof, mimetic thereof or combination thereof, wherein the component is capable of ameliorating symptoms of Coronavirus infection and wherein the plant species is selected from the group consisting of Nigella sativa, Thymus capitatus, Thymus vulgaris, Origanum syriacum, Thymbra spicata, Satujera thymbra, Sesamum indicum and Rhus coriaria Gynostemma petaphyllum, Boswellia sacra and Panax ginseng, or any plant containing tryptophan preventing or treating Coronavirus in the subject.
-
公开(公告)号:US20240165188A1
公开(公告)日:2024-05-23
申请号:US18526617
申请日:2023-12-01
申请人: TRINUTRA LTD.
IPC分类号: A61K36/71 , A61K31/015 , A61K31/05 , A61K31/122 , A61K31/20 , A61P17/08 , A61P31/04 , A61P31/10
CPC分类号: A61K36/71 , A61K31/015 , A61K31/05 , A61K31/122 , A61K31/20 , A61P17/08 , A61P31/04 , A61P31/10 , A61K2236/31
摘要: The present invention is directed to a method for treating and/or preventing skin, mucosal and systemic conditions resulting from microbial overgrowth, imbalance or infections comprising administering a composition to a mammalian subject, wherein said composition comprises oil obtained from Nigella sativa seeds, and wherein said oil comprises thymoquinone at a concentration of at least 2.5% w/w and one or more free fatty acids (FFAs) at a concentration of 2.5% w/w or less. The present invention is also directed to dosage forms comprising the aforementioned composition.
-
公开(公告)号:US11957727B2
公开(公告)日:2024-04-16
申请号:US17395249
申请日:2021-08-05
IPC分类号: A61K36/82 , A61K31/09 , A61K31/122 , A61K31/26 , A61K31/353 , A61K36/31 , A61K36/45 , A61K36/71 , A61P25/28
CPC分类号: A61K36/82 , A61K31/09 , A61K31/122 , A61K31/26 , A61K31/353 , A61K36/31 , A61K36/45 , A61K36/71 , A61P25/28
摘要: Disclosed are means, methods, and therapeutic compositions for prevention of memory loss during situations of neuroinflammation. In one embodiment the invention teaches administration of the therapeutic combination of ingredients comprising of pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal suffering from inflammation in order to preserver memory function.
-
公开(公告)号:US11951146B2
公开(公告)日:2024-04-09
申请号:US17534292
申请日:2021-11-23
发明人: Thomas Ichim , Timothy G. Dixon , Famela Ramos , Wais Kaihani
IPC分类号: A61K36/82 , A61K31/09 , A61K31/122 , A61K31/155 , A61K31/26 , A61K31/352 , A61K36/31 , A61K36/45 , A61K36/71 , A61P31/14 , A61P37/04
CPC分类号: A61K36/82 , A61K31/09 , A61K31/122 , A61K31/155 , A61K31/26 , A61K31/352 , A61K36/31 , A61K36/45 , A61K36/71 , A61P37/04
摘要: Disclosed are means, compounds, and compositions of matter useful for stimulation of natural killer cell activity. On one embodiment a composition termed QuadraMune™ comprised of pterostilbene, Nigella sativa extract, green tea extract, and broccoli. In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of metformin, pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal in need of natural killer cell immune modulation. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients with COVID-19.
-
-
-
-
-
-
-
-
-